Emergent Testing Lab LLC

Emergent Testing Lab LLC was paid $1.94M by Medicaid between Jan 2021 and Dec 2024, across 29 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 50% of everything it billed.

Compared with peers

Next to other Emergency Medicine Physician providers in Georgia

Rank by total paid#12 of 106

Median peer was paid$14K

This provider vs. median142×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	10,748	$278K
2022	9,557	$308K
2023	1,261	$66K
2024incomplete	40,397	$1.29M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	50%	12,881	6,389	$974K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	25%	10,405	8,992	$478K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.1%	13,497	6,617	$177K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.4%	7,906	6,976	$105K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	3.8%	2,610	1,072	$73K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.9%	5,685	3,344	$56K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.8%	1,102	892	$36K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.1%	2,652	2,246	$22K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	113	67	$5K
80306		<1%	206	65	$3K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	461	372	$2K
84443	Thyroid stimulating hormone (TSH)	<1%	611	480	$2K

17 more codes

80053	Comprehensive metabolic panel	<1%	626	$1K
80061	Lipid panel	<1%	535	$1K
83036	Hemoglobin; glycosylated (A1C)	<1%	633	$1K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	491	$737.93
84481		<1%	156	$511.18
84439		<1%	156	$281.82
85027		<1%	221	$234.33
36415	Collection of venous blood by venipuncture	<1%	663	$167.59
80048	Basic metabolic panel (calcium, ionized)	<1%	99	$125.69
82607		<1%	27	$96.93
82746		<1%	29	$95.53
84153		<1%	44	$40.20
83735		<1%	28	$27.64
82570		<1%	43	$22.41
82043		<1%	43	$12.18
84156		<1%	16	$5.16
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	24	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGOSS, JONATHAN (OWNER)

Same official

Other billing entities under GOSS, JONATHAN

Full network →

Provider	Location	Paid
Etl- Northeast LLC	Doraville, GA	$3.89M
Advanced Pathology Laboratory LLC	Brooklyn, NY	$4K
Emergent Testing LLC	Atlanta, GA	$2K
Emergent Testing of Texas PLLC	Houston, TX	$913.25

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.